Page last updated: 2024-10-20

thymine and Pseudomyxoma Peritonei

thymine has been researched along with Pseudomyxoma Peritonei in 1 studies

Pseudomyxoma Peritonei: A peritoneal adenocarcinoma characterized by build-up of MUCUS in the PERITONEAL CAVITY. Mucus secreting cells may attach to the peritoneal lining and continue to secrete mucus. The majority of cases represent tumor spread from a primary low-grade mucinous neoplasm of the APPENDIX (NCI Thesaurus).

Research Excerpts

ExcerptRelevanceReference
"Pseudomyxoma peritonei is a rare disease with a reported prevalence of about 1-3 per million people annually."5.62A case of pseudomyxoma peritonei successfully treated with trifluridine/tipiracil (TAS-102) and bevacizumab after palliative debulking surgery. ( Gohda, Y; Hayama, N; Hirano, S; Igari, T; Miyazaki, H; Shimizu, S; Yano, H, 2021)
"Pseudomyxoma peritonei is a rare disease with a reported prevalence of about 1-3 per million people annually."1.62A case of pseudomyxoma peritonei successfully treated with trifluridine/tipiracil (TAS-102) and bevacizumab after palliative debulking surgery. ( Gohda, Y; Hayama, N; Hirano, S; Igari, T; Miyazaki, H; Shimizu, S; Yano, H, 2021)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Hirano, S1
Gohda, Y1
Miyazaki, H1
Hayama, N1
Shimizu, S1
Igari, T1
Yano, H1

Other Studies

1 other study available for thymine and Pseudomyxoma Peritonei

ArticleYear
A case of pseudomyxoma peritonei successfully treated with trifluridine/tipiracil (TAS-102) and bevacizumab after palliative debulking surgery.
    Chinese clinical oncology, 2021, Volume: 10, Issue:3

    Topics: Bevacizumab; Cytoreduction Surgical Procedures; Drug Combinations; Humans; Male; Middle Aged; Perito

2021